CMC2 and malaria: As we consistently see accumulation of antibody responses against DC13 and peptides located in both DBLα1.7_D2 and DBLβ3_D4 domains at convalescence (day 30) compared to admission (day 0), we tested for reactivity of these plasma samples against peptides from MSA antigen (Fig. 4A–C), which often serves to measure a level of exposure to malaria parasites.